A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

NCT01634243 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: SPM 962

Sponsor

Otsuka Pharmaceutical Co., Ltd.